Continuous Levodopa-Carbidopa-Entacapone Delivery for Stable Dopamine Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders like Parkinson's disease fail to maintain stable dopamine levels due to fluctuations in levodopa plasma concentrations, leading to symptoms such as 'afternoon wearing off', and existing administration methods are inefficient in managing individual pharmacokinetic profiles.
Innovation Solution
A strategy involving a high initial dose (20-35% of the total daily dose) followed by continuous administration of a pharmaceutical composition containing levodopa, carbidopa, and entacapone, which includes a dopamine decarboxylase inhibitor and a COMT inhibitor, to maintain stable dopamine levels throughout the day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered in conventional dosing regimens, then dopamine concentration in the brain fluctuates, but this leads to symptoms such as 'afternoon wearing off' and requires increased dosage throughout the day
Solution Approach 1:
The patent applies preliminary action by administering a high initial dose (20-35% of total daily dose) at the start of treatment to establish stable baseline dopamine levels before transitioning to continuous lower-dose administration. This preliminary high dose ensures adequate dopamine concentration is achieved early, preventing afternoon wearing off symptoms while maintaining overall stability throughout the day.
Solution Approach 2:
The patent implements continuity of useful action through continuous administration of levodopa combined with carbidopa and entacapone after the initial dose. This continuous delivery method maintains steady plasma concentrations of levodopa, ensuring consistent dopamine production in the brain without the fluctuations that cause symptom recurrence in conventional intermittent dosing regimens.
2Productivity
If levodopa plasma concentration is increased to control symptoms, then symptom relief improves, but fluctuations in concentration occur leading to wearing off effects
Solution Approach 1:
The patent uses carbidopa as an intermediary substance that inhibits peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain intact. Entacapone serves as another intermediary by inhibiting COMT enzyme activity, preventing premature metabolism of levodopa. These intermediary substances enable sustained levodopa availability in plasma without requiring concentration fluctuations, thus maintaining both effectiveness and stability.
Solution Approach 2:
The patent applies parameter changes by modifying the dosing strategy from intermittent high-dose administration to continuous low-dose administration following an initial high dose. This parameter change in administration pattern, combined with the addition of carbidopa and entacapone, transforms the plasma concentration profile from fluctuating to stable, maintaining therapeutic levels throughout the day without wearing off effects.
3Quantity of substance
If a high first dose is administered (20-35% of total daily dose), then bioavailability of dopamine replacement agent is maintained at high level, but total daily dose requirement is reduced
Solution Approach 1:
The patent applies preliminary action by administering a high initial dose (20-35% of total daily dose) to rapidly establish adequate dopamine replacement levels and ensure high bioavailability at the critical start of treatment. This preliminary high dose maximizes therapeutic effect early, allowing the remaining 65-80% of the total daily dose to be administered continuously at lower rates, thereby reducing the overall quantity of substance required while maintaining sustained bioavailability.
Solution Approach 2:
The patent implements continuity of useful action by transitioning from the initial high dose to continuous administration of the remaining dosage. This continuous delivery ensures sustained bioavailability of the dopamine replacement agent throughout the day without requiring additional high doses, thereby maintaining therapeutic levels while reducing the total daily dose requirement compared to conventional intermittent dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach maintains consistent dopamine levels, reducing the total daily dose requirement and alleviating symptoms by ensuring a gradual increase in plasma concentrations, thereby addressing the variability in patient needs.
Implementation Method 1
dopamine is formed by decarboxylation of the precursor levodopa (L-dopa; L-3,4-dihydroxyphenylalanine) through the enzyme aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase (DDC))
Implementation Method 2
a dopamine decarboxylase inhibitor and a COMT inhibitor
Implementation Method 3
a dopamine decarboxylase inhibitor and a COMT inhibitor
Data Source
Figure 1~2
Figure 3
AI summary
A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI),and (iii) a COMT inhibitor where the composition is continuously administrated.